Plasma protein binding of celecoxib in mice, rat, rabbit, dog and human

Biopharmaceutics and Drug Disposition

Volumn 20, Issue 6, 1999, Pages 293-299

  Paulson, Susan K ^a   Kaprak, Todd A ^a   Gresk, Christopher J ^a   Fast, Douglas M ^a   Baratta, Mike T ^a   Burton, Earl G ^a   Breau, Alan P ^a   Karim, Aziz ^a  

^a PFIZER INC   (United States)

Author keywords

Celecoxib; Cyclooxygenase 2; Plasma protein binding

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; OROSOMUCOID; PLASMA PROTEIN; SERUM ALBUMIN;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MOUSE; NONHUMAN; NORMAL HUMAN; PLASMA PROTEIN BINDING; RABBIT; RANDOMIZED CONTROLLED TRIAL; RAT;

ADULT; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD PROTEINS; CYCLOOXYGENASE INHIBITORS; DOGS; FEMALE; HUMANS; MALE; MICE; OROSOMUCOID; PYRAZOLES; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; SULFONAMIDES;

EID: 0033383255     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199909)20:6<293::AID-BDD188>3.0.CO;2-X     Document Type: Article

References (15)

1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin like drugs. Nature (New Biol) 1971; 231: 23-235.
2. Smith JH, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nature (New Biol) 1971; 231: 235-237.
3. Raz A, Wyche A, Siegel N, Needleman P. Regulation of fibroblast cyclooxygenase synthesis by interleukin-1. J Biol Chem 1988; 263: 3022-3028.
4. Masferrer JL, Seibert K, Zweifel B, Needleman P. Endogenous glucucorticoids regulate an inducible cyclooxygenase enzyme. Proc Natl Acad Sci USA 1992; 89: 3917-3921.
5. Masferrer JL, Zweifel BS, Manning PT, Hauser DS, Leahy KM, Smith WG, Isakson PC, Seibert K. Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994; 91: 3228-3232.
6. Seibert K, Zhang Y, Lehy K, Hauser S, Masferrer J, Perkins W, Lee L, Isakson P. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994; 91: 12013-12017.
7. Penning TD, Talley JJ, Bertenshaw SR., Carter JD, Collins PW, Docter S, Graneto, MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DJ, Yu SS, Anderson GD, Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY, Isakson PC. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]bezenesulfonamide (SC-58635, celecoxib). J Med Chem 1997; 40: 1347-1365.
8. Isakson P, Zweifel B, Masferrer J, Koboldt C, Seibert K, Hubbard R, Geis S, Needleman P. Specific COX-2 inhibitors: from bench to bedside. In: Vane J, Botting J (eds), Selective COX-2 Inhibitors: Pharmacology, Clinical Effects and Therapeutic Potential. London: J. Kluwer Academic Publishers and William Harvey Press, 1998; 127-133.
9. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093-1095.
10. Langman LJ, LeGatt DF, Yatscoff RW. Blood distribution of mycophenolic acid. Ther Drug Monit 1994; 16: 602-607.
11. Rowland M. Plasma protein binding and therapeutic drug monitoring. Ther Drug Monit 1980; 2: 29-37.
12. Pacifici GM, Viani A. Methods of determining plasma and tissue binding of drugs. Clin Pharmacokinet 1992; 23: 449-468.
13. Routledge PA. The plasma protein binding of basic drugs. Br J Clin Pharmacol 1986; 22: 499-506.
14. Sansom LN, Evans AM. What is the true clinical significance of plasma protein binding displacement interactions? Drug Safety 1995; 12: 227-233.
15. Maziasz TJ, Seibert K, Khan NK, Paulson SK, Isakson PC. Preclinical pharmacologyof celecoxib and demonstration of superior GI safety compared with NSAIDs in dogs. Arthritis Rheum 1997; 40: S195.